Bacteria Linked To Unipharma Recall In August Identified By FDA In April
Executive Summary
FDA says in warning letter that Unipharma was in violation of labeling rules for OTC nasal sprays as well as being non-compliant with drug GMP requirements for documenting adherence to specifications.